Fox Chase Cancer Center News

SAN ANTONIO (DECEMBER 7, 2015) – Researchers from Caris Life Sciences^® and Fox Chase Cancer Center – Temple Health announced the presentation of two studies revealing the potential for exploring new therapeutic options for triple-negative breast cancer (TNBC) at the 2015 San Antonio Breast Cancer Symposium (SABCS).

Temple Health educators are working to disseminate colorectal cancer information tailored to the needs of underserved Latino populations, as part of the National Cancer Institute’s (NCI) Center to Reduce Cancer Health Disparities (CRCHD), National Outreach Network (NON).

PHILADELPHIA (November 6, 2015) – Temple University Hospital earned the status of a “Blue Distinction Center for Transplants” by Blue Cross Blue Shield, in recognition of the Fox Chase-Temple University Hospital Bone Marrow Transplant (BMT) Program’s expertise in performing adult bone marrow transplants.

PHILADELPHIA (November 6, 2015) – A recent preclinical investigation of a novel small molecule called ONC201 suggests it could potentially offer therapeutic benefits for patients diagnosed with either triple negative or non-triple negative breast cancer. Researchers at Fox Chase Cancer Center – Temple Health presented these findings at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston from Nov. 5-9, 2015.

PHILADELPHIA (November 5, 2015) – Fox Chase Cancer Center and NBC10 weekend news anchor/reporter Denise Nakano join forces to host Together Facing Lung Cancer, a FREE event designed to provide lung cancer survivors, caregivers, friends, family and healthcare providers to learn more about lung cancer screening and treatment. This event will take place on Thursday, November 19, from 6:00 until 8:00 pm, in the Fox Chase Cafeteria (333 Cottman Avenue in Philadelphia, Pa). Dinner will be served.

PHILADELPHIA (October 20, 2015) – Treatment of early-stage breast cancer with fewer, larger doses of radiation results in equivalent clinical outcomes as conventional radiation therapy, according to new research by Fox Chase Cancer Center – Temple Health investigators. The study revealed no significant difference in survival rates or long-term side effects in patients who received either intense (hypofractionated) radiation therapy over a four-week period or standard radiation therapy over a six- to seven-week period. The eight-year results of the prospective Phase II study were presented October 20 at the 57th Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Antonio, Texas.

PHILADELPHIA (October 19, 2015) – In the biggest study to date evaluating patients with nonmetastatic, large, invasive breast cancers, survival rates were found to be similar for patients treated with either breast conservation surgery and radiation, or mastectomy, according to an analysis published in Cancer.

PHILADELPHIA (October 19, 2015) – Fewer, larger radiation doses did not significantly impact quality-of-life outcomes for prostate cancer patients but may result in potentially worse outcomes for individuals with preexisting urinary problems, according to new research from Fox Chase Cancer Center – Temple Health investigators.